XTEND-Kids data confirm the efficacy and safety profile of ALTUVIIIO with simple, weekly 50 IU/kg dosing for both adults and children ALTUVIIIO’s expanding evidence of a first and best-in-class ...
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. ST. LOUIS – When it comes to bleeding ...
COPENHAGEN, Denmark and CAMBRIDGE, Mass., June 24, 2025 /PRNewswire/ -- Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved ...
Sutacimig Phase 2 interim results demonstrate >50% reduction in treated bleeding event and prophylactic treatment potential in Glanzmann thrombasthenia HMB-002 clinical proof-of-mechanism data in Von ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results